

November 9, 2011

For Immediate Release

Company Name: INTAGE Inc.
Representative: Kenji Miyakubi, President and
Representative Director
(Code: 4326, First Section of Tokyo Stock Exchange)
Contact: Osamu Kudo, Member of the Board
Telephone: +81-3-5294-0111

Notice of Revision to Forecasts of Financial Results

INTAGE Inc., in light of recent development of operating results, has revised its forecasts of financial results announced on May 11, 2011.

Revision to Forecasts of Financial Results

Revision to the Forecast of Consolidated Financial Results for the Whole-Year Period of the Year Ending March 31, 2012 (April 1, 2011 to March 31, 2012)

	Net sales	Operating income	Recurring profit	Net income	Net income per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecast (A)	38,262	3,163	3,149	1,659	165.04
Revised Forecast (B)	36,649	2,687	2,641	1,410	140.24
Change (B-A)	(1,613)	(476)	(507)	(249)	
Percent Change (%)	(4.2)	(15.1)	(16.1)	(15.0)	
<Reference> Results for the previous year (Year ended March 31, 2011)	36,538	3,465	3,438	1,915	190.51

Reasons for the Revisions

As presented in "Flash Report [Japanese GAAP] (Consolidated Basis) Results for the Six Months ended September 30, 2011" announced today (November 9, 2011), while Market Research and Consulting segment orders greatly improved and posted increased sales and profits year-on-year from the second quarter with a pickup in business confidence, sales and profits were both down sharply in the Drug Development Solutions segment. Despite increased monitoring services sales, the Drug Development Solutions segment suffered from weak new orders for data management and analysis services.

As a result of these developments, while the consolidated performance for the first half of FY2012 achieved sales around the same level and higher profits compared with the performance forecasts, the sales and profits were both down year-on-year.

From the third quarter forward, while the Company expects the performance of the Market Research and Consulting and the System Solutions segments to basically proceed as planned, in Drug Development Solutions the data management and analysis services sales remain sluggish.

The Company expects Drug Development Solutions to post declines in both sales and profits in the second half as well, and has revised the consolidated performance forecasts for FY2012 announced May 11, 2011 accordingly.

In Drug Development Solutions, INTAGE will implement a structural reorganization to strengthen sales capabilities, and rebuild this business to place it back on track.

Note: The forward-looking statements made in this document, including the aforementioned forecasts, are based on all information available to the management at the time of this document's release. Actual results may differ from the results anticipated in the statements.

---End of document---